Open AccessThe use of micro-costing in an economic analysis of allogeneic HSCT in Brazil
Author(s) -
Dora Fraga Vargas,
Caroline David,
Jaqueline Driemeyer Correia Horvath,
Tatiana Silva,
Mariana Pereira,
Lisandra Della Costa Rigoni,
Ivaine Taís Sauthier Sartor,
Gabriela Oliveira Zavaglia,
Luciane Beatriz Kern,
Thainá Luft,
Fernanda Tolves,
Fernanda Scherer,
Jaina Pereira,
Fabiano Barrionuevo,
Ana Paula Beck da Silva Etges,
Bruna Stella Zanotto,
Liane Esteves Daudt,
Luciane Nascimento Cruz,
Carísi Anne Polanczyk,
Cláudia Caceres Astigarraga
Publication year - 2021
Publication title -
jornal brasileiro de economia da saúde
Language(s) - English
Resource type - Journals
eISSN - 2359-1641
pISSN - 2175-2095
DOI - 10.21115/jbes.v13.n2.p166-74
Subject(s) - activity based costing , hematopoietic stem cell transplantation , medicine , health care , total cost , population , health economics , operations management , transplantation , surgery , environmental health , business , public health , nursing , economics , accounting , economic growth
Objective: The objective of this study was to estimate treatment costs of Hematopoietic stem cell transplantation (HSCT) at a reference center in Brazil. Methods: The study population consisted of patients from the Unified Health System HSCT who underwent HSCT in southern Brazil between 2016 and 2019. Costs were measured using a micro-costing approach, based on Time-Driven Activity-based Costing (TDABC) adapted for economic studies in health and included the following steps: definition of the research question, structured data collection, and statistical analysis of results. Results: The total cost of HSCT was $155,110 ($92,794 – $249,146 USD). Matched unrelated donor HSCT was more expensive than matched related donor HSCT. The major cost factors involve post-ransplant complications, mainly the occurrence of infections. Concerning cost composition, exams and procedures represent the largest expense in HSCT (45%). Conclusion: These estimates could be applicable to further evaluations for HSCT cost-effectiveness and help healthcare decision-makers in middle-income countries